Publications by authors named "M S Gilabert"

Introduction: Patients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening.

Methods: A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022.

View Article and Find Full Text PDF

Background: Brain metastases (BM) are rare in pancreatic ductal adenocarcinoma (PDAC) and little data exists concerning these patients and their outcomes.

Aim: We aimed to analyze the management, practices, and outcomes of patients presenting BM from PDAC both in our institution and in all cases reported in the literature.

Methods: We conducted a retrospective, monocentric analysis using a data mining tool (ConSoRe) to identify all patients diagnosed with PDAC and BM in our comprehensive cancer center (Paoli-Calmettes Institute), from July 1997 to June 2022 (cohort 1).

View Article and Find Full Text PDF

New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit.

View Article and Find Full Text PDF

The inactivatedsevere acute respiratory syndrome coronavirus 2 vaccine (CoronaVac) has been the principal vaccine used in Chile's prebooster immunization campaign. We compared major outcomes in 206 hospitalized vaccinated adults vs 507 unvaccinated adults (mid-2021). Individuals in the vaccinated group were much older, required less critical care, had lower mortality (adjusted by age), and had shorter hospitalization than those in the unvaccinated group.

View Article and Find Full Text PDF
Article Synopsis
  • Multikinase inhibitors, particularly tyrosine kinase and immune checkpoint inhibitors, are advancing cancer treatment, while proton pump inhibitors (PPIs) are often overprescribed for common digestive issues despite potential risks.* -
  • Long-term PPI use may lead to serious side effects in cancer patients, such as bone fractures and nutrient deficiencies, and can hinder the effectiveness of certain cancer therapies by impacting drug absorption.* -
  • The altered gut microbiome from prolonged PPI use can undermine the benefits of immune checkpoint inhibitors, prompting oncologists to reconsider PPI prescriptions and effectively communicate the risks about drug interactions to patients.*
View Article and Find Full Text PDF